Fig. 4

The anti-nociceptive effect of MJN110 in the mTBI mice was dependent on the cannabinoid receptor activation. MJN was co-administered with either the CB1R antagonist AM281 (3 mg/kg) or the CB2R receptor antagonist AM630 (3 mg/kg) in the mTBI mice once a day for a total of 7 days. Treatment with MJN showed a significant reduction of allodynia at 6 and 14 days post-TBI. Combination of MJN with AM630 partially reversed MJN110 mediated anti-allodynic effect on days 6 and 14; while combination of MJN with AM281 resulted in significantly decreased tactile threshold compared to the MJN alone treated group on day 14. *p < 0.05 and **p < 0.01 (n = 15/group)